Clinical Trial Update: A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms [Phase 2]

View source ↗

Summary

Phase 2 study in systemic sclerosis evaluating Avenciguat (BI 685509) for effects on lung function and other symptoms; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Avenciguat

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Scleroderma, Systemic | Phase 2 | Status: COMPLETED